Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity. 2004

Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
Laboratoire de Chimie Bioorganique, UMR 6001 CNRS, Université de Nice Sophia-Antipolis, Parc Valrose, 06108 Nice Cédex 2, France. vierling@unice.fr

With the aim of improving the pharmacological properties of current protease inhibitors (PIs), the synthesis of various acyl and carbamate amino acid- or diglyceride-containing prodrugs derived from saquinavir, indinavir and nelfinavir, their in vitro stability with respect to hydrolysis and their anti-HIV activity in CEM-SS and MT4 cells have been investigated. l-Leucine (Leu) and l-phenylalanine (Phe) were connected through their carboxyl to the PIs while l-tyrosine (Tyr) was conjugated through its aromatic hydroxyl via various spacer units. Hydrolysis of the prodrug with liberation of the active free drug was crucial for antiviral activity. The Leu- and Phe-PI prodrugs released the active free drug very rapidly (half-lives of hydrolysis in buffer at 37 degree C of 3-4 h). The Tyr-PI conjugates with a -C(O)(CH(2))(4)- linker exhibited half-lives in the 40-70 h range and antiviral activities in the 21-325 nM range (from 2 to 22 nM for the free PIs). The chemically very stable carbamate "peptidomimetic" Tyr-PI prodrugs (no hydrolysis detected after 7 days in buffer) displayed a very low anti-HIV activity or were even inactive (EC(50) from 2300 nM to >10 microM). A very low antiviral activity was measured for the diglyceride-substituted saquinavir and for all of the disubstituted indinavir and nelfinavir prodrugs. All these prodrugs probably released the active parent PI too slowly under the antiviral assay conditions. These results combined with those from transepithelial transport studies (Rouquayrol et al., Pharm. Res., 2002, 19, 1704-1712) indicate that conjugation of amino acids (through their carboxyl) to the PIs constitutes a most appealing alternative which could improve the intestinal absorption of the PIs and reduce their recognition by efflux carriers.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D019258 Saquinavir An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. Invirase,Ro 31-8959,Saquinavir Mesylate,Saquinavir Monomethanesulfonate,Saquinivir,Monomethanesulfonate, Saquinavir,Ro 31 8959,Ro 318959
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
March 2000, Antiviral chemistry & chemotherapy,
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
January 2010, The American journal of tropical medicine and hygiene,
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
October 2002, Journal of pharmaceutical and biomedical analysis,
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
August 1997, Pharmacy world & science : PWS,
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
January 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
May 2001, Journal of chromatography. B, Biomedical sciences and applications,
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
April 1999, Journal of chromatography. B, Biomedical sciences and applications,
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
April 2001, Journal of acquired immune deficiency syndromes (1999),
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
April 2001, The Journal of antimicrobial chemotherapy,
Bérangère Gaucher, and Marielle Rouquayrol, and Dominique Roche, and Jacques Greiner, and Anne-Marie Aubertin, and Pierre Vierling
June 2001, Journal of chromatography. B, Biomedical sciences and applications,
Copied contents to your clipboard!